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The arginyltransferase Ate1 is a component of the N-end rule
pathway, which recognizes proteins containing N-terminal degra-
dation signals called N-degrons, polyubiquitylates these proteins,
and thereby causes their degradation by the proteasome. At least
six isoforms of mouse Ate1 are produced through alternative
splicing of Ate1 pre-mRNA. We identified a previously uncharacter-
ized mouse protein, termed Liat1 (ligand of Ate1), that interacts
with Ate1 but does not appear to be its arginylation substrate. Liat1
has a higher affinity for the isoforms Ate11A7A and Ate11B7A. Liat1
stimulated the in vitro N-terminal arginylation of a model substrate
by Ate1. All examined vertebrate and some invertebrate genomes
encode proteins sequelogous (similar in sequence) to mouse Liat1.
Sequelogs of Liat1 share a highly conserved ∼30-residue region that
is shown here to be required for the binding of Liat1 to Ate1. We
also identified non-Ate1 proteins that interact with Liat1. In contrast
to Liat1 genes of nonprimate mammals, Liat1 genes of primates are
subtelomeric, a location that tends to confer evolutionary instability
on a gene. Remarkably, Liat1 proteins of some primates, from ma-
caques to humans, contain tandem repeats of a 10-residue se-
quence, whereas Liat1 proteins of other mammals contain a single
copy of this motif. Quantities of these repeats are, in general, dif-
ferent in Liat1 of different primates. For example, there are 1, 4, 13,
13, 17, and 17 repeats in the gibbon, gorilla, orangutan, bonobo,
neanderthal, and human Liat1, respectively, suggesting that repeat
number changes in this previously uncharacterized protein may con-
tribute to evolution of primates.
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The N-end rule pathway recognizes proteins containing N-terminal degradation signals called N-degrons, polyubiquitylates
these proteins, and thereby causes their degradation by the protea-
some (Fig. 1 A and B) (1–9). The main determinant of an N-degron
is a destabilizing N-terminal residue of a protein. Recognition
components of the N-end rule pathway are called N-recognins. In
eukaryotes, N-recognins are E3 ubiquitin (Ub) ligases that can target
N-degrons (Fig. 1). Bacteria also contain a (Ub-independent) ver-
sion of the N-end rule pathway (10, 11).
Regulated degradation of proteins or their fragments by the
N-end rule pathway mediates a strikingly broad range of functions,
including: the sensing of heme, nitric oxide, oxygen, and short
peptides; control of protein quality and subunit stoichiometries,
including the elimination of misfolded proteins; regulation of
G proteins; repression of neurodegeneration; regulation of apo-
ptosis, chromosome cohesion/segregation, transcription, and DNA
repair; control of peptide import; regulation of meiosis, autoph-
agy, immunity, fat metabolism, cell migration, actin filaments,
cardiovascular development, spermatogenesis, and neurogenesis;
the functioning of adult organs, including the brain, muscle and
pancreas; and the regulation of many processes in plants (4–9)
(Fig. 1 A and B; see Supporting Information for an expanded leg-
end and references to this figure).
In eukaryotes, the N-end rule pathway consists of two branches.
One branch, called the Ac/N-end rule pathway, targets proteins for
degradation through their Nα-terminally acetylated (Nt-acetylated)
residues (Fig. 1B) (2, 3, 12). Degradation signals and E3 Ub ligases
of the Ac/N-end rule pathway are called Ac/N-degrons and Ac/N-
recognins, respectively. Nt-acetylation of cellular proteins is appar-
ently irreversible, in contrast to acetylation-deacetylation of internal
Lys residues. Approximately 90% of human proteins are cotrans-
lationally Nt-acetylated by ribosome-associated Nt-acetylases (13).
Posttranslational Nt-acetylation occurs as well. Many, possibly most,
Nt-acetylated proteins contain Ac/N-degrons (Fig. 1B) (2–4, 12).
The pathway’s other branch, called the Arg/N-end rule pathway,
targets specific unacetylated N-terminal residues (Fig. 1A) (3,
14–16). The “primary” destabilizing N-terminal Arg, Lys, His,
Leu, Phe, Tyr, Trp, and Ile, are directly recognized by N-recog-
nins. The unacetylated N-terminal Met, if it is followed by a bulky
hydrophobic (Φ) residue, also acts as a primary destabilizing res-
idue (Fig. 1A) (3). In contrast, unacetylated N-terminal Asn, Gln,
Asp, and Glu (as well as Cys, under some metabolic conditions)
are destabilizing because of their preliminary enzymatic mod-
ifications, which include N-terminal deamidation (Nt-deamida-
tion) of Asn and Gln and Nt-arginylation of Asp, Glu, and
oxidized Cys (Fig. 1A) (4, 6, 7, 17).
Nt-arginylation is mediated by the Ate1-encoded arginyl-
transferase (Arg-tRNA-protein transferase; R-transferase), a
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component of the Arg/N-end rule pathway and a subject of the
present study (Fig. 1 A and D) (18–23). Alternative splicing of
mouse Ate1 pre-mRNAs yields at least six R-transferase iso-
forms, which differ in their Nt-arginylation activity (Fig. 1 C and
D) (18, 21). R-transferases are sequelogous (similar in sequence)
(24) throughout most of their ∼60-kDa spans from fungi to
mammals (4). R-transferase can arginylate not only N-terminal
Asp and Glu, but also N-terminal Cys, if it has been oxidized
to Cys-sulfinate or Cys-sulfonate, through reactions mediated
by NO, oxygen, and N-terminal Cys-oxidases (6, 7, 20). The
resulting circuits can act as sensors of NO and oxygen in a cell
through reactions that start with a conditional oxidation of
N-terminal Cys in proteins such as the Rgs4, Rgs5, and Rgs16
regulators of G proteins in mammals (4, 20, 25) and specific
transcriptional regulators in plants (reviewed in refs. 4, 6, and 7).
There are dozens of either identified Nt-arginylated proteins
(including natural protein fragments) or proteins that are pre-
dicted to be Nt-arginylated. Many, possibly most, of these pro-
teins are conditionally or constitutively short-lived substrates of
the Arg/N-end rule pathway (Fig. 1A) (14, 15, 20, 26, and ref-
erences therein). In contrast, there were, until now, no analyzed
protein ligands of R-transferase that did not appear to be its
substrates. We describe a previously uncharacterized mouse
protein, termed Liat1 (ligand of Ate1) that binds to the mouse
Ate1 R-transferase, is apparently not arginylated by it, and has
a higher affinity for specific splicing-derived Ate1 isoforms. We
Fig. 1. The mammalian N-end rule pathway and the Ate1 arginyltransferase (R-transferase). See introductory paragraphs for a summary of the pathway’s
mechanistic aspects and biological functions. N-terminal residues are denoted by single-letter abbreviations. A yellow oval denotes the rest of a protein
substrate. (A) The Arg/N-end rule pathway. It recognizes proteins through their unacetylated N-terminal residues and contains the N-terminal arginylation
(Nt-arginylation) branch, mediated by the arginyltransferase (R-transferase) Ate1 and by the Nt-amidases Ntan1 and Ntaq1 that act upstream of Ate1 (4–6).
(B) The Ac/N-end rule pathway. It recognizes proteins through their Nα-terminally acetylated (Nt-acetylated) residues (2, 3, 12). Red arrow on the left indicates
the removal of the N-terminal Met residue by Met-aminopeptidases (MetAPs). N-terminal Met is retained if a residue at position 2 is larger than Val. (C) The
bidirectional DfaPAte1 promoter upstream of exon 1B of the mouse Ate1 gene (4, 21, 27). (D) Four major mouse Ate1 R-transferase isoforms and their des-
ignations (4, 21). See Supporting Information for a detailed legend and supplementary references to this figure.
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also identified proteins other than R-transferase that appear to
interact with Liat1. Remarkably, Liat1 proteins of some pri-
mates, from macaques to humans, contain tandem repeats of
a 10-residue sequence, in contrast to a single copy of this motif in
Liat1 of other mammals. Quantities of repeats in Liat1 are, in
general, different among different primates, suggesting that re-
peat number changes in this previously uncharacterized protein
may contribute to evolution of primates.
Results
Alternative Ate1 Exons and Their Sequelogies (Sequence Similarities).
The 59-kDa mouse R-transferase is encoded by Ate1. This gene,
located on chromosome 7 (7-F3), contains 14 protein-coding
exons that encompass, together with introns, ∼128 kb of Ate1 DNA
(Fig. 1 C and D) (18, 21, 23, 27). Mouse Ate1 encodes at least six
splicing-derived Ate1 isoforms. Fig. 1D shows designations and
exon compositions of the four major isoforms; they are enzymati-
cally active R-transferases whose levels of expression vary among
different mouse tissues (21). The splicing of Ate1 pre-mRNAs
involves transcription from two distinct Ate1 promoters and the
alternative utilization of two exon pairs: (i) either exon 1A or 1B,
and (ii) either exon 7A or 7B (Fig. 1 C and D). The alternative
exons 1A and 1B encode two sequelogous (24) ∼30-residue
N-terminal regions of R-transferase (Fig. 1D and Fig. S1) (21). The
alternative exons 7A and 7B encode two sequelogous 43-residue
regions of R-transferase (Fig. 1D and Fig. S1).
Two-Hybrid Detection of a Protein That Interacts with Ate1. In a
search for mouse proteins that specifically interact with mouse
R-transferase without being arginylation substrates, we used
a yeast-based two-hybrid (Y2H) assay, using a mouse testis cDNA
library and a Gal4 DNA-binding domain (DBD)–Ate11B7A fusion
as bait. This screen identified nine independent positive DNA
clones encoding different (overlapping) segments of a previously
uncharacterized mouse protein (LOC74230; Acc. NP_941039)
(Fig. 2A). This 228-residue protein, encoded by a single-copy
mouse gene, was termed Liat1 (Fig. 3A).
To verify and expand these results, we expressed, in Saccharo-
myces cerevisiae of appropriate genetic backgrounds, Gal4 DBD
fusions to three mouse Ate1 isoforms, Ate11B7A, Ate11A7A or
Ate11B7B, and a Gal4–activation domain (AD) fusion to the full-
length mouse Liat1. These strains were assayed for their ability to
grow on minimal (SD) media lacking Leu, Trp, His, and Ade,
thereby indicating the presence or absence of interactions among
the examined protein fusions. The results were in agreement with
the findings by the initial two-hybrid screen in that the Ate11B7A
R-transferase isoform interacted with Liat1 (Figs. 1D and 2A).
Fig. 2. Detection and characterization of interactions between the mouse Ate1 R-transferase and a previously uncharacterized mouse protein termed Liat1. (A)
Detection of Ate1–Liat1 interactions using a Y2H assay. A Gal4 DBD–Ate11B7A fusion and other DBD-based fusions (e.g., a control DBD fusion containing theWASP
protein) vs. coexpressed Gal4–AD fusions to full-length Liat1 and to other proteins, including specific Ate1 isoforms as well as the control (WASP-interacting) Cdc42
protein. The ability to grow on minimal media lacking Leu, Trp, His, and Ade was used to detect interactions among the examined protein fusions. See SI Ex-
perimental Procedures for additional information. (B) Detection of Ate1–Liat1 interactions using co-IP assays with mouse cell extracts. Plasmids expressing 3haLiat1
and specific Ate1 isoforms were transiently expressed in mouse Ate1−/− EF cells, followed by immunoprecipitations with anti-ha antibody, SDS/PAGE of immu-
noprecipitates, and immunoblotting with both anti-ha and anti-Ate1 antibodies. (C) Same as in B but using purified mouse 3haLiat1 and purified mouse Ate1
isoforms, with immunoprecipitation by anti-Ate1 antibody.
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However, the two-hybrid assay did not detect interactions of
Liat1 with the Ate11A7A and Ate11B7B isoforms, in contrast to the
Ate11B7A isoform (Figs. 1D and 2A). This result was unexpected
because differences among Ate1 isoforms are significant but not
large, given sequelogies (24) between the encoded sequences of the
Ate1 exons 1A vs. 1B (36% identity) and 7A vs. 7B (30% identity),
respectively (Fig. 1D and Fig. S1). Although the affinity of
Ate11A7A and Ate11B7B for Liat1 was too low for detection by two-
hybrid assays (in contrast to the affinity of Ate11B7A) (Figs. 1D and
2A), an immunoprecipitation assay, described below, did detect
a complex between Liat1 and the Ate11A7A isoform. One ramifi-
cation of these two-hybrid results was a high likelihood that the
interaction between Liat1 and Ate11B7A was specific, given the
ability of Liat1 to distinguish, in its binding patterns, among three
similar Ate1 isoforms (Figs. 1D and 2A, and Fig. S1).
A Region of Liat1 Required for Interaction with Ate1. The Y2H assay
was also used, using the mouse Ate11B7A isoform and either
N-terminal/C-terminal truncations or internal deletions of
mouse Liat1, to delineate a region of Liat1 that was required for
Fig. 3. Mouse Liat1 and the mapping of its Ate1-binding region. (A) Nucleotide sequence of mouse Liat1 cDNA and amino acid sequence features of mouse
Liat1 (NP_941039). A large black “I” after the Lys-rich region denotes the position of a single 2,737-bp intron between two protein-coding exons in the Liat1
genomic DNA. The purple, green, yellow, and blue rectangles denote, respectively, the negatively charged region of mouse Liat1, its positively charged
region, its particularly highly conserved ∼30-residue domain, termed the Liat1 domain, and a 10-residue region that becomes tandemly repeated in Liat1 of
some primates, including humans, but is a single-copy sequence in Liat1 of other mammals, including mouse Liat1. The same color scheme is used to denote
these regions of Liat1 in other figures of this paper. Black and red numbers on the left indicate nucleotide and amino acid residue numbers, respectively. See
also the main text and Figs. S2–S4. (B) Mapping Liat1–Ate1 interactions using Y2H assays. The Gal4 DBD–Ate11B7A fusion was examined, using Y2H, for
interactions with the coexpressed Gal4–AD fusion to either full-length Liat1 or to the indicated AD fusions encoding Liat1 fragments. The results of this assay
are summarized on the right, and the color coding of Liat1 domains (the same as in A) is indicated on the left.
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the observed interaction (Figs. 2A and 3B). Liat1113-165,
a 53-residue internal segment of the 228-residue Liat1 that
contained a particularly strongly conserved ∼30-residue region
(termed the Liat1 domain; see below and Fig. S2) was sufficient
for the Liat1–Ate11B7A interaction, whereas the Liat1 domain
alone did not suffice (Fig. 3B). It was also found that only a part
of the Liat1 domain was required for the binding of a C-termi-
nally truncated Liat1 to Ate11B7A, provided that a region im-
mediately upstream of the Liat1 domain was present as well
(Fig. 3B).
Coimmunopreciptation Assays. We also transiently coexpressed, in
mouse Ate1−/− embryonic fibroblasts (EFs) lacking R-transferase
(19), the N-terminally triple ha-tagged mouse Liat1 (3haLiat1)
and one of the four untagged mouse R-transferases, Ate11A7A,
Ate11B7A, Ate11A7B, or Ate11B7B (Figs. 1D and 2B). 3haLiat1 in
cell extracts was immunoprecipitated with anti-ha antibody, fol-
lowed by SDS/PAGE and immunoblotting with either anti-ha or
the previously characterized, affinity-purified antibody to mouse
Ate1 (20). The results of these coimmunoprecipitation (co-IP)
assays were reproducible in independent assays and showed an
efficacious co-IP of 3haLiat1 with Ate11A7A (Fig. 2B, lanes 6 and
8). A less efficacious but still detectable co-IP with Ate11B7A was
also observed (Fig. 2B, lane 4 vs. lanes 6 and 8), whereas
co-IP with the isoforms Ate11A7B and Ate11B7B was negligible
(Fig. 2B).
We also carried out co-IP assays with recombinant proteins
that had been expressed in Escherichia coli using the Ub fusion
technique and were purified by affinity chromatography that
included the removal of Ub moiety (28, 29). These procedures
yielded purified 3haLiat1 and purified, untagged Ate11A7A,
Ate11B7A, Ate11A7B or Ate11B7B. Equal amounts of Ate11A7A,
Ate11B7A, Ate11A7B, or Ate11B7B were incubated with an
∼fourfold molar excess of purified full-length 3haLiat1, followed
by immunoprecipitation with anti-Ate1, SDS/PAGE, and im-
munoblotting with either anti-ha or anti-Ate1 (Fig. 2C). These
“carrier-free” co-IP assays with purified proteins (instead of cell
extracts containing these proteins) detected interactions between
Liat1 and all four Ate1 isoforms (Fig. 2C). Note, however, that
co-IPs of purified 3haLiat1 with purified Ate11B7A and Ate11A7A
were significantly more efficacious than co-IPs with the other
two isoforms, Ate11A7B and Ate11B7B (Fig. 2C, lanes 1 and 3 vs.
lanes 2 and 4). These results were in qualitative agreement with
the findings by both two-hybrid assays and co-IP assays with cell
extracts, neither of which could detect Liat1 interactions with the
isoforms Ate11A7B and Ate11B7B (Fig. 2 B and C). In addition,
co-IPs with purified Liat1 and purified Ate11B7A or Ate11A7A
(Fig. 2C) indicated that Liat1–Ate1 interactions did not re-
quire other proteins.
We do not understand the cause of the reproducible differ-
ence in which Ate11B7A was the only Liat1-interacting Ate1
isoform in two-hybrid assays (Figs. 2A and 3B), whereas
Ate11A7A was the apparently highest-affinity Liat1-interacting
Ate1 isoform in co-IP assays with cell extracts (Fig. 2B).
A plausible possibility is a different pattern of modifications
(e.g., phosphorylation) of Ate11B7A vs. Ate11A7A that influences
the outcomes of two different kinds of binding experiments
(protein fusions in Y2H assays in vivo vs. epitope-tagged 3haLiat1
and untagged Ate1 in co-IP assays with mammalian cell extracts
in vitro). The other two isoforms, Ate11A7B and Ate11B7B, were
negative in regard to interactions with Liat1 in both two-hybrid
assays and co-IP assays with cell extracts (Figs. 2B and 3B). The
noninteracting (or weakly interacting) Ate11A7B and Ate11B7B
isoforms both contained the 7B exon, in contrast to the other
two Ate1 isoforms (Fig. 1D and Fig. S1).
Sequence Features of the Mouse Liat1 Protein. The mouse Liat1
cDNA (1700016K19Rik; Acc. NM_198637) encodes a 228-resi-
due (25.5 kDa), previously uncharacterized protein (NP_941039)
with a deduced pI of 7.45 (Fig. 3A). The Liat1 gene, located on
the mouse chromosome 11-B5, contains a single 2,737-bp intron
between two protein-coding exons, and no alternative mouse
Liat1 cDNA isoforms could be detected in databases (Figs. 3A
and 4). Amino acid sequence features of mouse Liat1 include
a negatively charged 10-residue region (9 of 10 residues are Glu)
and a positively charged 12-residue region (11 of 12 residues are
basic, largely Lys) (Fig. 3A). These regions are present in Liat1 of
all examined mammals, but Liat1 of other vertebrates can lack
either one of the two charged regions or both of them (Fig. 4B).
An aspect of Liat1 that is particularly conserved in evolution is
a ∼30-residue region termed the Liat1 domain (Figs. 3 and 4,
and Figs. S2–S4). The 32-residue mouse and human Liat1
domains are 96% identical (Figs. S2 and S3). Genomes of all
examined vertebrates—and of some invertebrates as well—
encode proteins sequelogous to mouse Liat1 (Fig. 4 and Figs.
S2–S4). All sequelogs of Liat1 share at least the ∼30-residue
Liat1 domain. In fact, among vertebrates other than mammals
and in Liat1-containing invertebrates as well, the Liat1 domain is
often the only region that identifies a protein as a sequelog of
mammalian Liat1 (Figs. 3 and 4 and Figs. S2–S4).
The extent of conservation of the Liat1 domain among
mammals (>95%) and a weaker but still considerable conser-
vation of this domain between, for example, mammals and
invertebrates, such as sea anemone or acorn worm (Fig. 4 and
Figs. S2–S4), indicate a purifying selection that maintained this
Ate1-interacting domain (of unknown function) in the course of
animal evolution. At the same time, large clades of organisms,
including plants and fungi, lack proteins that can be identified as
Liat1 through sequelogies (sequence similarities) alone, as dis-
tinguished from still possible spalogies (spatial similarities) (24).
Tandem Repeats of a 10-Residue Motif in Liat1 of Primates. Another
feature of mammalian Liat1 is a 10-residue sequence immedi-
ately downstream of the Liat1 domain (Figs. 3 and 4 and Fig.
S3). This 10-residue motif is present as a single copy in non-
primate mammalian Liat1 proteins, but in Liat1 of some pri-
mates, including humans, this sequence is tandemly repeated
(Fig. 4 and Fig. S3). For example, there are 4, 13, 13, 17, 17, and
18 repeats in the, gorilla, orangutan, bonobo, neanderthal, hu-
man, and baboon Liat1, respectively (Fig. 4 and Fig. S3). At the
same time, some primates, such as gibbon and bushbaby, contain
just one copy of the 10-residue motif, similarly to nonprimate
mammals (Fig. 4 and Fig. S3). The specific sequences of 10-
residue repeats in a tandem array are either identical or nearly
identical to each other both within a given Liat1 and among
Liat1 proteins of different primate species (e.g., Fig. S3).
The probability of mutations that alter the quantity of repeats
in a gene can be orders of magnitude higher than the probability
of, for example, missense mutations (Discussion) (30, 31). As
a result, genetic variation that stems from repeat number
changes in specific proteins can greatly exceed variation caused
by other changes. This difference would be even higher if a gene
in question is subtelomeric (Discussion) (31). Liat1 genes are
subtelomeric in all examined primates, including humans (32),
and most (although not all) primate Liat1 proteins contain tan-
dem repeats of the 10-residue motif (Fig. 4 and Fig. S3). In
contrast, Liat1 genes of nonprimate mammals are not sub-
telomeric, and all such Liat1 proteins contain one copy of the 10-
residue motif (Fig. 4A).
The possibility that differences, among primates, in the
quantities of their 10-residue repeats (Fig. 4) signify a role for
these repeats in primate evolution is considered in the Discus-
sion. In contrast to nonprimate Liat1, still unresolved aspects of
subtelomeric primate Liat1 genes are complicated enough to
preclude definitive conclusions about expression patterns of, for
example, human Liat1 (called C17orf97 in databases) until its
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DNA, pre-mRNAs, and mature mRNAs are extensively char-
acterized. For example, current descriptions of human Liat1
(C17orf97) (www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.
cgi?db=human&l=C17orf97) are consistent with the existence
of at least one additional intron in the region of human Liat1
repeats, in contrast to mouse Liat1, which lacks both a second
intron and the tandem repeats (Figs. 3A and 4 and Fig. S3)
(Discussion).
Expression of Liat1 in Mouse Tissues and in Mouse or Human Cell
Lines. A commercial antibody to human C17orf97 (Liat1) was
raised in rabbits against a 93-residue internal segment that in-
cluded the highly conserved 32-residue human Liat1 domain,
which is 96% identical to its counterpart in mouse Liat1 (Fig. 3A
and Figs. S2 and S3). In immunoblots of extracts from mouse
tissues or NIH 3T3 mouse cell line, this anti-Liat1 antibody
detected largely a single band at the expected ∼26 kDa Mr of
mouse Liat1 in the heart, kidney, liver, spleen, testis, lung, thy-
mus, pancreas, and brown adipose tissue, and in NIH 3T3 cells as
well (Fig. 5B, lanes 1–5, and Fig. 5C, lanes 1–9). Immunoblotting
with decreasing amounts of purified recombinant (untagged)
mouse Liat1 indicated that this antibody to human Liat1 could
detect down to ∼50 ng of mouse Liat1 per lane (Fig. 5A). At this
(moderate) sensitivity, little if any Liat1 was detected in the total
mouse brain, hippocampus, cerebellum, and white adipose tissue
(Fig. 5B, lane 6, and Fig. 5C, lanes 1–3). We note that histochemical
data in the Human Protein Atlas (HPA023583), produced
through the use of the same antibody, suggested the presence
of Liat1 (C17orf97) in the human brain (www.proteinatlas.org/
ENSG00000187624/tissue). In situ hybridization of a mouse
1700016K19Rik (Liat1) cDNA to sections of mouse brain indicated
the presence of Liat1 mRNA at least in the cerebellum (mouse.
brain-map.org/experiment/show?id=69114594).
Immunoblotting with extracts from human HeLa and
HEK293T cells detected two Liat1 species of ∼55 kDa and ∼50
kDa (Fig. 5C, lanes 10 and 11). Human Liat1 is predicted to be
423 residues long (46.4 kDa) because of 17 tandem repeats in
human Liat1 of a 10-residue sequence, in contrast to a single copy
of this sequence in the 228-residue (25.5 kDa) mouse Liat1 and
other nonprimate Liat1 proteins (Fig. 3, 4, and 5C, lanes 10 and
11). A smaller of two human Liat1 species in Fig. 5C (lanes 10
and 11) may be either a cleavage product of the larger human
Liat1 or a pre-mRNA splicing-derived Liat1 isoform. Remarkably,
this human Liat1 immunoblotting pattern also contained an ∼26-
kDa band that comigrated with the ∼26-kDa band recognized by
the same antibody in mouse tissues (Fig. 5C, lanes 10 and 11 vs.
lanes 4–9). These results are consistent with the existence of hu-
man Liat1 isoforms in which quantities of the 10-residue repeat
can vary between ∼17 and 1, a functionally remarkable possibility
that will be followed up through a more detailed understanding of
primate Liat1 genes.
Effect of Liat1 on Ate1-Mediated Nt-Arginylation. The previously
characterized in vitro Nt-arginylation assay (21) used [14C]-L-Arg,
Fig. 4. Chromosomal locations of Liat1 genes and evolution of Liat1 proteins. (A) Liat1 genes are located away from telomeres in both mice (chromosome
11-B5) and other nonprimate mammals. In contrast, Liat1 genes are subtelomeric in all examined primates (e.g., human chromosome 17-p13.3), indicating
a translocation of Liat1 to a subtelomeric site in an ancestor of modern primates, from gibbons and bushbabies to macaques and humans. (B) Evolution of
Liat1 proteins. The colors of rectangles (the same as in Fig. 3A) denote, respectively, the negatively charged region of Liat1 (purple), its positively charged
region (green), its particularly highly conserved ∼30-residue domain (the Liat1 domain) (yellow), and a 10-residue segment that becomes tandemly repeated
in Liat1 of some primates (blue). In all examined Liat1 proteins that contain these regions they are present in the same (indicated) order. Although each of
these regions, in a given Liat1, is unambiguously recognizable upon inspection of its amino acid sequence, the “linear” distances between these regions are
not identical even among mammals and are particularly variable among nonmammalian Liat1 proteins (Figs. S3 and S4). This aspect of Liat1 is largely
bypassed in these diagrams, the chief aim of which is to highlight the presence or absence of specific regions and the emergence of tandem 10-residue
repeats in Liat1 of some primates, including humans and great apes. Dashed and shifted rectangles in Liat1 of nonmammalian vertebrates and invertebrates
signify a nonconservation of distances between specific domains of Liat1 in the indicated organisms, in comparison with a significant (although incomplete)
conservation of interregion distances among mammalian Liat1 proteins. See also the main text and Figs. S2–S4. For the accession numbers of specific Liat1
proteins and for Latin names of the cited animal species, see the legend to Fig. S2.
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purified mouse Ate11A7A, Ate11B7A, Ate11A7B, and Ate11B7B iso-
forms, an Arg-tRNA–generating system, and either bovine
α-lactalbumin (it bears the Nt-arginylatable N-terminal Glu resi-
due) (Fig. S5B) or purified C-terminally tagged recombinant
reporters X-DHFRbt (X = Asp, Cys or Arg-Cys) based on the
mouse dihydrofolate reductase [DHFR (the “bt” tag is described
in ref. 17)]. X-DHFRbt contained the six-residue sequence
KGLAGL immediately after the N-terminal X residue (X = Asp,
Cys or Arg-Cys), followed by the DHFRbt moiety. KGLAGL is
the sequence of mouse Rgs4 (a physiological Arg/N-end rule
substrate; see introductory paragraphs) immediately after its wild-
type N-terminal Cys (20).
Initially, identical amounts of the individual purified Ate11A7A,
Ate11B7A, Ate11A7B, and Ate11B7B isoforms were incubated for 60
min at 37 °C with the rest of assay’s components, including [14C]-L-Arg
and X-DHFRbt (X = Asp, Cys, or Arg-Cys), and either with or
without Ate1-lacking extract from mouse Ate1−/− EFs, fol-
lowed by SDS/PAGE and autoradiography (Fig. S5A). As
expected (21), all Ate1 R-transferase isoforms could Nt-
arginylate the N-terminal Asp residue of Asp-DHFRbt, with
Ate11B7B being most active, and with Ate11B7A, Ate11A7A, and
Ate11A7B, exhibiting respectively, ∼66%, ∼65%, and ∼12% of
the activity of Ate11B7B (Fig. S5A). No Nt-arginylation of the
“pre-arginylated” Arg-Asp-DHFRbt was observed under any
conditions (Fig. S5A), as expected, given the specificity of
R-transferase (Fig. 1A) (4). There was no detectable Nt-arginylation
of Cys-DHFRbt in the absence of extract from Ate1−/− EF cells, but
this reporter was Nt-arginylated in the presence of extract, pre-
sumably because of the oxidation of N-terminal Cys by compounds
in cell extracts (7, 20).
The Liat1-supplemented version of this assay (without extract
from Ate1−/− EF cells) used X-DHFRbt (X = Asp, Cys). Each of
the Ate11A7A, Ate11B7A, Ate11A7B, and Ate11B7B isoforms was
preincubated for 30 min at 37 °C with an ∼fourfold molar excess
of purified untagged mouse Liat1 or with buffer alone before
their addition to the arginylation assay. The Nt-arginylation of
Asp-DHFRbt by Ate1 was reproducibly enhanced in the pres-
ence of Liat1, from 1.3-fold to 2.3-fold (Fig. S5C). This effect is
unlikely to stem from increased macromolecular crowding upon
the addition of Liat1, because the addition of equal or larger
amounts of BSA did not alter the efficacy of Nt-arginylation. The
unknown mechanistic cause of moderate but reproducible effects
of Liat1 on Nt-arginylation is a subject for future studies.
Significantly, we could not detect—despite attempts to do so—
the conjugation of 14C-Arg to Liat1 itself in this assay, in either the
presence or absence of test proteins, such as α-lactalbumin or
X-DHFRbt. (Upon SDS/PAGE, the untagged mouse Liat1 migrates
significantly below the band of X-DHFRbt.) Even overexposures of
autoradiograms of electrophoretically fractionated proteins
after 14C-arginylation in the presence of purified Liat1 did not
reveal any significant 14C in the vicinity of the ∼26-kDa Liat1
band, indicating that Liat1 is not an Ate1 substrate.
Identification of Liat1-Binding Proteins Other than Ate1. We also
carried out a search for mouse proteins other than Ate1 that
interact with mouse Liat1 (Fig. 3A), using a library of mouse
brain cDNAs fused to the Gal4 AD vis-á-vis Liat1 cDNA fused
to the Gal4 DBD. This screen identified ∼40 different mouse
proteins that appeared to bind to mouse Liat1, with the corre-
sponding cDNA isolates having passed standard controls of the
Y2H assay (Fig. S6C). In addition, an independent Y2H screen
for interactions among protein methyltransferases and proteins
that bind to them (including their substrates) identified the hu-
man Jmjd6 methyltransferase as a putative ligand of human
C17orf97 (33) (i.e., the human Liat1 protein) (Fig. S6C).
We also searched for protein interactions with Liat1 using GST-
pulldowns with GST-Liat1 and extracts from mouse EF cells (Fig.
S6A). These MS-based assays added the ribosomal proteins S14
and S19 as well as three specific histones to the Y2H-based list of
other Liat1 ligands (Fig. S6). Thus, identified putative ligands of
Liat1 encompassed a broad range of functional classes, including
components of the translation, transcription, and Ub-proteasome
systems. Our ongoing co-IP assays that independently verify the
Fig. 5. Analyses of Liat1 proteins by immunoblotting. (A) Purified recombinant (untagged) mouse Liat1 was fractionated by SDS/PAGE, following by im-
munoblotting with an antibody to a highly conserved region of human Liat1 (C17orf97) (see the main text). Lanes 1–3: 25, 50, and 100 ng of mouse Liat1 per
lane, respectively. (B) Same as in A, but with extracts from the indicated mouse tissues that had been fractionated by SDS/PAGE. An asterisk indicates a larger,
apparently unrelated (cross-reacting) protein species in extracts from thymus and white adipose tissue (WAT). The results of immunoblotting with antitubulin
antibody are shown as well. (C) Lanes 1–8, same as in B, with extracts from indicated mouse tissues. Lane 9, same as in lanes 1–8 but an extract from mouse
NIH 3T3 cells. Lanes 10, 11, same as lane 8 but extracts from human HeLa and HEK293T cells. Larger human Liat1 proteins, presumably corresponding to
species with multiple tandem repeats (see Fig. 4 and the main text), are indicated on the right. A question mark denotes a putative Liat1 species from human
cell lines that comigrates with the much smaller (26 kDa) mouse Liat1 and may contain just one copy of the 10-residue motif that is tandemly repeated in
other species of human Liat1 (see the main text).
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binding of Liat1 to its putative ligands [which were detected by
Y2H or GST-pulldowns (Fig. S6C)] have recently confirmed that
Jmjd6 and the ribosomal protein S14 can be coimmunoprecipi-
tated with mouse Liat1 from a cell extract (Fig. S6B). These and
other binding assays with putative ligands of Liat1 will continue to
verify the current preliminary list (Fig. S6), thereby making pos-
sible systematic analyses of confirmed Liat1 ligands in regard to
specific functions of their interactions with Liat1.
Discussion
We identified a 26-kDa mouse protein, termed Liat1, by detecting
its binding to the 59-kDa mouse Ate1 R-transferase, a component
of the Arg/N-end rule pathway (Figs. 1–3). The Liat1–Ate1 in-
teraction was shown to require at least a part of the highly con-
served ∼30-residue region of Liat1 (Fig. 3B). Biological functions
of Liat1–Ate1 interactions (Figs. 2 and 3) remain to be understood,
in part because Liat1 is a previously uncharacterized protein. (In
current databases, human Liat1 is called C17orf97.) We also
identified putative Liat1-binding proteins other than Ate1 (Fig.
S6), but the biological function of Liat1 remains to be discovered.
Further analyses showed that Liat1 proteins of some primates,
from macaques to humans, contain tandem repeats of a 10-res-
idue sequence, in contrast to a single copy of this motif in Liat1
of other mammals, including rodents. Quantities of these repeats
are, in general, different in Liat1 of different primates. For ex-
ample, there are 4, 13, 13, 17, and 17 repeats in the gorilla,
orangutan, bonobo, neanderthal, and human Liat1, respectively
(Fig. 4 and Fig. S3), suggesting that repeat number changes in
Liat1 might play a role in evolution of primates. As evidence,
these differences in the quantities of Liat1 repeats do not rise
above a correlational argument, and the current disposition is
further complicated by our finding of intraspecies variability in
the number of repeats. For example, the Liat1 proteins encoded
by an anonymous human genome (NM_001013672) and by
the genome of James D. Watson (www.ncbi.nlm.nih.gov/IEB/
Research/Acembly/av.cgi?db=human&l=C17orf97) were found
to contain 17 tandem repeats in each, whereas the genome of J. Craig
Venter encodes Liat1 that contains 18 repeats (NP_001013694).
Analyses of primate genomes have so far identified relatively
few alterations that could be demonstrated to contribute to
phenotypic differences among these species. The “causative”
alterations include variants of developmental enhancer DNA
sequences as well as specific alleles of genes that influence cir-
cadian rhythms, human brain size, language, other human traits,
and differences in body sizes among primates (34–37). On evo-
lutionary timescales the emergence of anatomical and behavioral
features that distinguish humans from great apes was remarkably
fast, because the last common ancestor of humans and chim-
panzees lived about 6 million y ago.
The efficacy of selection pressure is limited by the extent of
relevant genetic variation within a breeding population. We
suggest, therefore, that the rapidity of evolution that led to
humans may have involved proteins containing tandemly re-
peated sequences, given frequent changes in the numbers of such
repeats. Analogous arguments have been made both in general
and to account for the strikingly rapid (in less than 1,000 y)
emergence of modern dog breeds, in response to selection
pressures imposed by breeders (30, 38). Morphological differ-
ences among dog breeds, and even within a breed, were found to
correlate with variations in the numbers of one-residue or two-
residue repeats in proteins that regulate embryonic development
and postnatal growth (30).
Tandem repeats of amino acid sequences that range in size
from 1 to more than 100 residues are a feature of many cellular
proteins (30, 36, 38, 39). Heritable changes in the number of
repeat units are known to underlie a significant fraction of
phenotypic variability both among different species and within
a species (36, 38). The previously demonstrated genetic in-
stability of repeats stems from several causes, including unequal
crossover, DNA replication slippage, and double-strand break
repair (30, 31). In an evolving species, genetic variation that
results from repeat number changes in specific proteins can
greatly exceed variation that is caused, for example, by missense
mutations. This difference would be even higher if a gene in
question is subtelomeric, because proximity to a telomere tends
to increase the frequency of recombination-mediated changes in
the quantity of repeats in a gene (31).
Remarkably, Liat1 genes are subtelomeric in all examined
primates, including humans, and most primate Liat1 proteins
contain tandem repeats of a 10-residue motif (Fig. 4 and Fig. S3).
Potentially telling exceptions include the gibbon and bushbaby
Liat1 proteins, which contain a single copy of the 10-residue
motif that is repeated in other examined primates (Fig. 4B) (37).
In contrast to primate Liat1 genes, their counterparts in other
mammals, including the mouse, are not subtelomeric (Fig. 4A),
and all predicted nonprimate Liat1 proteins in databases contain
one copy of the 10-residue motif. The function of Liat1 repeats
(Fig. 4) and their possible relevance to anatomic and phenotypic
evolution of primates remain to be addressed.
One subtelomeric gene encoding a protein that contains tan-
dem repeats is Drd4 (40). A human dopamine receptor encoded
by Drd4 contains varying numbers of tandem repeats of a 16-
residue sequence that forms the third cytosolic loop of the re-
ceptor. Both the quantity of 16-residue repeats and specific
sequences within each repeat are often altered among individual
humans, with repeat numbers varying between 2 and 10 (40).
Analogous polymorphisms of these repeats were also observed in
Drd4 of other primates (40). Human Drdr4 receptors with dif-
ferent repeat numbers were reported to differ in functional
properties, and were also differentially regulated in diseases such
as schizophrenia. Nevertheless, there is still no definitive evi-
dence that the observed frequencies of Drd4-encoded isoforms
containing different quantities of repeats had been caused, at
least in part, by positive selection, as distinguished from a quasi-
neutral drift (41).
In sum, a major unanswered question is whether changes in
repeat quantities among Liat1 proteins of different primates
stemmed, at least in part, from specific selection pressures. The
alternative scenario is that most variation in Liat1 repeats (Fig. 4
and Fig. S3) may be the result of genetic drift and unselected
fixations of altered repeat quantities, because of a small effective
population size of an evolving species, including occasional
population bottlenecks. A smaller population is characterized by
correspondingly weaker forces of natural selection. Near-neutral
evolution of proteins under such conditions is discussed by Lynch
(42). Because small changes in Liat1 repeat numbers may have
modest phenotypic effects, a near-neutral drift would be likely to
at least contribute to evolution of repeats in Liat1. If so, it is the
selection-based, adaptation-centered hypothesis about a func-
tional role of repeat number changes in Liat1 that must be
experimentally verified vis-á-vis the competing null hypothesis,
in which these changes would be caused by a near-neutral
genetic drift.
The understanding of both Liat1 itself and the functional
significance of its binding to specific isoforms of the Ate1
R-transferase would be advanced by answers to at least the fol-
lowing questions. What are the composition and functions of in
vivo complexes that contain Ate1, Liat1, and other macromo-
lecular components? What is the biological function of Liat1?
How does this function relate to the known role of the Ate1
R-transferase in the Arg/N-end rule pathway (Fig. 1A)? Does
a divergent Liat1 protein—for example, the one of sea anemone
[it is identifiable as Liat1 solely through its ∼30-residue Liat1
domain (Figs. S2 and S4)—specifically bind to the sea anemone
Ate1? [The binding of mouse Liat1 to mouse Ate1 requires the
Liat1 domain and apparently does not involve the 10-residue
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motif that forms repeats in Liat1 of primates (Figs. 2, 3B, and 4,
and Figs. S2–S4).]
Furthermore, do repeats of the 10-residue motif in, for example,
human Liat1 (Fig. 4 and Fig. S3) interact with each other? Do these
repeats specifically bind to any human protein? If they do, does the
binding of Liat1 repeats to that protein also involve other regions of
human Liat1? Is there a counterpart of a human repeat-binding
protein in, for example, mouse cells? (Mouse Liat1 contains one
copy of the sequence that forms repeats in human Liat1.) As
mentioned in Results, it would also be essential to understand,
in detail, a primate (e.g., the human or macaque) Liat1 gene,
given its more complex organization (including the presence
of Liat1 isoforms) than the structure of repeat-lacking Liat1
genes of nonprimate mammals (Figs. 3A and 4).
The understanding of Liat1 would also benefit from con-
structing and characterizing mouse strains that either lack Liat1
or contain its counterpart in which the 10-residue motif had been
amplified to yield primate-like tandem repeats. It would also be
informative to determine—with a primate such as, for example,
macaque—the phenotypic effects of strongly increased or
strongly decreased quantities of 10-residue repeats in Liat1 (Fig.
4). [Gene-specific alterations of the macaque genome through
the clustered regularly interspaced short palindromic repeats
(CRISPR) technology have already been achieved (43).] Given
the preferential binding of Liat1 to specific isoforms of the Ate1
R-transferase (Fig. 2), further studies of Liat1 may also advance
the functional understanding of Ate1 isoforms. In addition, the
obscurity—until the present study—of tandem repeats in pri-
mate Liat1, and still incomplete descriptions of subtelomeric loci
among the sequenced metazoan genomes (because of complex-
ities of dealing with telomere-proximal microsatellite DNA
repeats), suggest that it may be informative to further explore
subtelomeric regions of the 23 human chromosomes for the
presence of other uncharacterized genes that might encode
repeats analogous to those of Liat1.
Experimental Procedures
Y2H Assays. Y2H assays were carried out with S. cerevisiae, using the BD
Matchmaker kit (BD Biosciences), the plasmid pCB132, which expressed
the Gal4DBD-ATE11B7A fusion (Table S1), and a mouse testis cDNA pACT
library (Clontech).
Construction and Expression of Recombinant Proteins in BL21 (DE3) E. coli. The
untagged mouse Ate11B7A, Ate11B7B, Ate11A7A, and Ate11A7B, the untagged
mouse Liat, and 3haLiat1 were expressed as Ub fusions in E. coli, followed by
the removal of Ub and purification of recombinant proteins by Mono-S
chromatography (SI Experimental Procedures).
In Vitro Arginylation Assay. The Nt-arginylation assay was performed essen-
tially as described previously (21).
Tissue Extracts and Immunoblotting. Extract preparation and immunoblotting
were carried out essentially as described previously (3, 12, 21).
GST Pulldown Assay and Immunoprecipitations. Mouse EF cells were tran-
siently transformed with a plasmid expressing either GST or a GST–Liat1
fusion, and GST-pulldown assays were carried out as described in SI Experi-
mental Procedures. Immunoprecipitations with anti-flag or anti-ha anti-
bodies were performed as previously described (3, 12).
Additional information regarding experimental procedures is given in
SI Experimental Procedures.
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